Drawn to Science: T-cell bispecific antibodies

http://youtu.be/w4iCian4tnQ Engineered antibodies can be designed to help the body’s own defence mechanisms fight diseases. At Roche Pharma Research and Early Development, we are working on a novel form of engineered antibodies for cancer immunotherapy that we call T-cell bispecific (TCB) antibodies. We consider them matchmakers between T cells and cancer cells. With two handles, they recognise specific markers on the surface of cancer cells. A third handle is designed to hook onto T cells, bringing the TCB antibodies in close proximity to the cancer cells. The T cells are then activated to attack the cancer cells. To learn more about Roche’s commitment to cancer immunotherapy, visit http://www.roche.com/cancer-immunotherapy. Subscribe to our YouTube channel now: https://www.youtube.com/user/roche?sub_confirmation=1 Get in touch with us: https://www.roche.com/ https://www.facebook.com/RocheCareers https://www.linkedin.com/company/roche https://twitter.com/roche Roche has been committed to improving lives since the company was founded in 1896 in Basel, Switzerland. Today, Roche creates innovative medicines and diagnostic tests that help millions of patients globally. Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. For more information and insights visit: https://www.roche.com/